Recent Finacing
Recent Raise
Pulmotect develops PUL-042, an inhaled dual TLR agonist therapy that amplifies lung epithelial innate immunity to provide pathogen-agnostic protection against viral, bacterial, and fungal respiratory infections; advancing clinical trials.
